Navigation Links
PRA Executive to Present at Outsourcing Conference
Date:7/20/2011

RALEIGH, N.C., July 20, 2011 /PRNewswire/ -- PRA, a leading Clinical Research Organization, announces that the head of our Scientific and Medical Affairs group, Kent Thoelke, will discuss critical issues in medical informatics and feasibility at the 3rd Annual Effective Business Development Outsourcing Relationships Conference being held 19-21 July 2011 in Philadelphia.

On Thursday, 21 July, Mr. Thoelke will co-host the session, "Rising to the Challenge of Global Feasibility through Medical Informatics." The presentation's highlights include using medical informatics as a data-driven approach to plan clinical trials, practical considerations for particular patient populations, and how to develop multi-country scenarios to meet enrollment milestones.

In his role as Senior Vice President at PRA, Mr. Thoelke directs our medical informatics and therapeutic expertise programs, providing scientific and strategic oversight of product development to empower project teams as they execute clinical trials on behalf of our clients. He has over 19 years of wide-ranging experience in global drug development and device industry. Having visited over 40 countries, he is familiar with the global drug development environment, and has established relationships with therapeutic experts in numerous indications around the world.

PRA's Medical Informatics group, which serves as a key component of our Scientific and Medical Affairs division, leads the industry in advancing evidence-based approaches for protocol validation, study feasibility and patient access.  To enhance global accrual rates for clinical trials, PRA has focused on mining public and private databases to create a proprietary methodology for patient and site access.

About PRA

PRA is transforming clinical trials through our people, innovation and transparency.  PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge.  Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs.  But at PRA, we are looking to the future, not the past.  Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email endpoints@praintl.com or call our Global Headquarters.


'/>"/>
SOURCE PRA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Joel Posener Joins PharmaNet as Executive Medical Director, Neuroscience
2. AquaStar Holdings, Inc. Subsidiary Appoints Former Beckman Coulter Executive as Vice President of Operations
3. Dr. David Heimbrook Appointed Chief Executive Officer of SAIC-Frederick, Inc.
4. Netsmart Technologies Names Michael Valentine as Chief Executive Officer
5. Practice Fusion Expands Executive Team with New VP of Marketing and Senior Business Development Director
6. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
7. Ed Weimer Joins Delta Point, Inc. as Executive Account Director
8. Pearl Therapeutics Appoints Charles (Chuck) Bramlage President and Chief Executive Officer
9. The Clearity Foundation Hires Hillary Theakston as Executive Director
10. Savient Pharmaceuticals Announces Executive Appointments
11. IDRI Announces Appointment of H. Stewart Parker as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/21/2016)... Massachusetts , March 22, 2016 ... facial recognition with passcodes for superior security   ... ), a leading provider of secure digital communications services, ... their biometric technology and offer enterprise customers, particularly those ... secure facial recognition and voice authentication within a mobile ...
Breaking Biology News(10 mins):